|
Eric Zitter focuses on deal origination and developing various corporate strategies for US market penetration, including international mergers and acquisitions, advising on the ADR process and US listings. Eric has established relationships with various VC’s, institutional buyers, fund managers, market makers, investment bankers and high net worth investors. Eric specializes in the life sciences / biotechnology industry and has launched the firm’s global biotechnology newsletters for the United Kingdom, Sweden, and Australia for distribution to the international financial community. Eric has researched and travelled globally searching for M&A opportunities for Global Markets Capital Group’s international client base. Previously, Eric was a Business Development Analyst at Quintiles Transnational, where he conducted research on potential blockbuster late Phase III/registered drugs as targets for new business opportunities, analyzed competitor companies as targets for possible acquisitions, and launched the company’s first weekly internal newsletter (Drug Digest) consisting of latest drug news, new drug approvals, and pipeline information. Eric holds a joint Bachelor of Science and Engineering in Bioengineering with a minor in Applied Economics from Cornell University. | 